Search results
Results from the WOW.Com Content Network
The vaccine prevents dengue caused by all four dengue virus serotypes. Since 2022, Dengvaxia has been available for use in children and adolescents 9–16 years old who have laboratory-confirmed previous dengue virus infection and are living in an area where dengue is endemic.
There is a growing public health need for effective preventive interventions against dengue, a disease caused by four viruses, termed serotypes 1–4. Two dengue vaccines have been licensed, Dengvaxia® (CYD-TDV), developed by Sanofi Pasteur, and Qdenga® (TAK-003), developed by Takeda.
Dengue vaccine is a vaccine used to prevent dengue fever in humans. [9] Development of dengue vaccines began in the 1920s, but was hindered by the need to create immunity against all four dengue serotypes. [10] As of 2023, there are two commercially available vaccines, sold under the brand names Dengvaxia and Qdenga. [11] [12]
Dengue vaccine can help protect against dengue in people who have had dengue in the past. Dengue is caused by one of four viruses spread through the bite of an infected mosquito. A person can get infected by any of the four dengue viruses.
A dengue vaccine provides your child with safe, effective, and long-lasting protection against dengue illness, hospitalization, and severe disease. Children need to be tested to confirm a previous dengue infection before vaccination. Three doses of the vaccine are required for full protection.
FDA approves first vaccine for prevention of dengue disease in people ages 9-16 who have laboratory-confirmed previous dengue infection and live in endemic areas, such as the U.S....
To get the dengue vaccine, one must meet three important criteria: The individual must live in a high-risk area. Simply visiting the area is not sufficient to qualify someone for this vaccine. They must be between 9 and 16 years of age.